In a phase 1b study of co-administered SC semaglutide 2.4 mg with cagrilintide 0.164.5 mg (CagriSema) in participants with overweight or obesity, cagrilintide exposure was proportional to dose and did not affect semaglutide exposure or elimination [7]
The timing, frequency, and length of treatment depend on the specific peptide used
Cells 8:246
Tbeta4 was used to treat N20.1 cells (premature oligodendrocyte cell line) in vitro, and the proliferation of N20.1 cells was measured by bromodeoxyuridine (BrdU) immunostaining
Neuronal activation mapping using cFos immunostaining in the area postrema (AP), nucleus tractus solitarius (NTS), and lateral parabrachial nucleus (LPBN) provided mechanistic insight
Identity, copper-binding integrity, purity, and sterility are documented